Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Vestal Point Capital LP

Vestal Point Capital LP boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 975,000 shares of the specialty pharmaceutical company's stock after acquiring an additional 75,000 shares during the quarter. Jazz Pharmaceuticals comprises approximately 7.1% of Vestal Point Capital LP's portfolio, making the stock its biggest holding. Vestal Point Capital LP owned about 1.61% of Jazz Pharmaceuticals worth $120,071,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 1.5% during the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after acquiring an additional 37,108 shares during the period. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Capital World Investors raised its holdings in Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after purchasing an additional 104,195 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 0.4%

JAZZ stock traded down $0.45 during midday trading on Thursday, hitting $107.82. The stock had a trading volume of 863,792 shares, compared to its average volume of 850,624. The company's 50-day moving average price is $113.50 and its 200 day moving average price is $121.91. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $6.65 billion, a PE ratio of 15.19, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the business earned $2.68 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on JAZZ shares. Barclays restated an "overweight" rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Piper Sandler reissued an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $182.79.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the transaction, the chief executive officer now owns 439,307 shares of the company's stock, valued at $51,113,369.45. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Seamus Mulligan purchased 100,000 shares of the firm's stock in a transaction on Friday, May 9th. The stock was bought at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares in the company, valued at $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 28,236 shares of company stock worth $3,956,190 in the last 90 days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.